Mr. Darren Lui, Aptorum Group Limited's President and Executive Director, has been appointed Chief Executive Officer, effective June 1, 2022. Mr. Lui succeeds Mr. Ian Huen, who will be stepping down as Chief Executive Officer, but will remain on the Company's board as a non-executive director on the same effective date. Mr. Lui's appointment comes as part of the Company's continued focus on the development and discovery of its therapeutics and diagnostics products.

Under Mr. Huen and Mr. Lui's stewardship, the Company has successfully brought two small molecule drugs (ALS-4 and SACT-1) from discovery to their respective completion of two phase I clinical trials and currently in preparation for their next phase of clinical trials in human patients, as well as conducting ongoing clinical validations of the Company's RPIDD program, a liquid biopsy based molecular diagnostics for infectious diseases. Mr. Lui has great understanding of the Company's current and ongoing operations and his appointment as CEO ensures continuity in the Company's leadership going forward. Mr. Huen's resignation is part of an organized and transparent succession plan, in benefit of all shareholders and stakeholders of the Company.